My Watchlist

BNY Mellon Municipal Income Inc. Common Stock

BNY Mellon Strategic Municipal Bond Fund, Inc. Common Stock

BNY Mellon Strategic Municipals, Inc. Common Stock

Big Digital Energy, Inc. - Common Stock

CorVel Corp. - Common Stock

Cwc Energy Services Corp

DEFSEC Technologies Inc. - common stock, no R/S concurrent with offering

FAT Brands Inc. - 8.25% Series B Cumulative Preferred Stock

FAT Brands Inc. - Class B Common Stock

FAT Brands Inc. - Warrant

Hikma Pharmaceuticals Plc.

Infrastructure and Energy Alternatives, Inc. - Common Stock

Iveda Solutions, Inc. - Common Stock

Kronos Worldwide Inc Common Stock

Livongo Health, Inc. - common stock

NLI Holdings, Inc. Common Stock

Navan, Inc. - Class A Common Stock

Nuveen Churchill Direct Lending Corp. Common Stock

State Street SPDR Dow Jones REIT ETF

TransUnion Common Stock

Valhi, Inc. Common Stock

Vinci Compass Investments Ltd. - Class A Common Shares

Vista Outdoor Inc. Common Stock

WisdomTree Efficient TIPS Plus Gold Fund

Edit Watchlist

Top Indices

Dow Jones Industrial Average

NASDAQ Composite

Standard & Poors 500

My Portfolio

Articles published by Amneal Pharmaceuticals, Inc.

< Previous 1 2 3 4 Next >

Amneal to Participate at Upcoming Investor Conference

May 22, 2024

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Reports First Quarter 2024 Financial Results

May 03, 2024

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

April 24, 2024

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine

April 16, 2024

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal to Report First Quarter 2024 Results on May 3, 2024

April 10, 2024

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal to Ring the Nasdaq Closing Bell on April 2, 2024

March 28, 2024

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension

March 25, 2024

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Reports Fourth Quarter and Full Year 2023 Financial Results

March 01, 2024

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203

February 27, 2024

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal to Participate at Upcoming Investor Conference

February 13, 2024

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024

January 31, 2024

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension

January 10, 2024

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023

January 04, 2024

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

December 21, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Announces Move to Nasdaq

December 15, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

December 07, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules

December 01, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Reports Third Quarter 2023 Financial Results

November 07, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal to Participate at Upcoming Investor Conferences

November 03, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance

October 23, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio

October 12, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal to Report Third Quarter 2023 Results on November 7, 2023

October 05, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection

September 06, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Receives First Product Approval in China

September 06, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate

September 06, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India

August 29, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal to Participate at the 2023 Wells Fargo Healthcare Conference

August 25, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease

August 24, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Reports Second Quarter 2023 Financial Results

August 04, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

July 26, 2023

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Tickers AMRX

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.